Karyopharm Therapeutics (NASDAQ:KPTI) Releases Earnings Results, Beats Estimates By $0.01 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports. The business had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the business posted ($0.30) earnings per share. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock traded up $0.01 during trading on Thursday, reaching $0.90. The company had a trading volume of 1,069,318 shares, compared to its average volume of 1,268,549. The firm’s 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $0.91. The company has a market capitalization of $112.21 million, a PE ratio of -0.75 and a beta of 0.16. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on KPTI shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Piper Sandler raised their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday. Robert W. Baird cut their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).